Topical formulation identified for prolonged graft survival in corneal transplants

Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, has announced the publication of key findings on its soluble recombinant human CD83 protein (sCD83) in cornea transplants… …read more